Equities Analysts Offer Predictions for UTHR Q1 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Investment analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of United Therapeutics in a research report issued on Monday, March 17th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $6.36 for the quarter, down from their previous estimate of $6.93. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics’ Q2 2025 earnings at $6.71 EPS, Q3 2025 earnings at $6.95 EPS, Q4 2025 earnings at $6.68 EPS, FY2025 earnings at $26.69 EPS, Q1 2026 earnings at $6.48 EPS, Q2 2026 earnings at $6.76 EPS, Q3 2026 earnings at $7.12 EPS, Q4 2026 earnings at $7.36 EPS, FY2026 earnings at $27.73 EPS and FY2027 earnings at $28.24 EPS.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm earned $4.36 EPS.

Other analysts have also recently issued research reports about the stock. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Trading Down 2.7 %

United Therapeutics stock opened at $314.12 on Wednesday. The company has a market capitalization of $14.11 billion, a price-to-earnings ratio of 13.80, a PEG ratio of 0.97 and a beta of 0.64. The stock’s 50 day moving average is $348.15 and its 200-day moving average is $357.92. United Therapeutics has a 12 month low of $221.53 and a 12 month high of $417.82.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics during the 4th quarter worth approximately $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics in the third quarter worth $33,000. Dunhill Financial LLC increased its holdings in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 50 shares during the period. State of Wyoming bought a new position in United Therapeutics during the 4th quarter worth $62,000. Finally, Millstone Evans Group LLC bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $67,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 90,255 shares of company stock valued at $32,614,521. 11.90% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.